EGFR-mutated non-small-cell lung cancer transformation into small-cell lung cancer after tyrosine kinase inhibitors: let us think about liquid biopsy!

被引：0
|
作者：
Pezzuto, F. [1 ]
Fortarezza, F. [1 ]
Lunardi, F. [1 ]
Tauro, V. [1 ]
Frega, S. [1 ]
Pasello, G. [1 ]
Calabrese, F. [1 ]
机构：
[1] Univ Padua, Padua, Italy
来源：
VIRCHOWS ARCHIV | 2021年 / 479卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-23-003
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [21] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Isamu Okamoto
    Kenji Tamura
    Masahiro Fukuoka
    Investigational New Drugs, 2007, 25 : 499 - 504
  • [22] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Ischemic stroke in a patient with EGFR-mutated non-small-cell lung cancer after treatment with ramucirumab
    Chen, Guo-Yu
    Cheng, Wen-Chien
    Tu, Chih-Yen
    THORACIC CANCER, 2022, 13 (23) : 3412 - 3414
  • [24] Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
    Lu, Yunyun
    Fan, Yun
    ONCOTARGETS AND THERAPY, 2016, 9 : 1135 - 1143
  • [25] Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S85 - S86
  • [26] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
  • [27] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Karima Saboundji
    Jean-Bernard Auliac
    Maurice Pérol
    Géraldine François
    Henri Janicot
    Marie Marcq
    Catherine Dubos-Arvis
    Aldo Renault
    Florian Guisier
    Luc Odier
    Radj Gervais
    Christos Chouaïd
    Targeted Oncology, 2018, 13 : 501 - 507
  • [29] Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
    Saalfeld, Felix Carl
    Moeller, Johanna
    Christopoulos, Petros
    Wenzel, Carina
    Rasokatf, Anna
    Wangg, Xuejun Alice
    Vathiotish, Ioannis
    Koenigi, David
    Illinij, Oliver
    Grohe, Christian
    Wiesweg, Marcel
    Wesseler, Claas
    Schubart, Christoph
    Pelusi, Natalie
    Rohde, Gernot
    Overbeck, Tobias R.
    Kirfel, Jutta
    Alt, Juergen
    Kauffmann-Guerrero, Diego
    Griesingerv, Frank
    Kulhavyw, Jonas
    Allgaeuer, Michael
    Klimovay, Anna
    Schuetz, Maret
    Aust, Daniela E.
    Hochmairj, Maximilian J.
    Rothschild, Sacha I.
    Syrigos, Konstantinos N.
    Veluswamy, Rajwanth
    Michels, Sebastian
    Stenzinger, Albrecht
    Joehrens, Korinna
    Wermke, Martin
    EUROPEAN JOURNAL OF CANCER, 2024, 213
  • [30] ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment
    Kato, Yasuhiro
    Tanaka, Yosuke
    Hino, Mitsunori
    Gemma, Akihiko
    RESPIRATORY MEDICINE CASE REPORTS, 2019, 27
12345